Inactive Instrument

InDex Pharmaceuticals Holding AB Stock Nasdaq Stockholm

Stocks

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

11:42am	Flerie enters into merger plan with Biosergen	FW
06:00am	Flerie's Bonsai Biotherapeutics Receives Clinical Trial Application Approval for Lead Drug Candidate	MT

Valuation: InDex Pharmaceuticals Holding AB

Market Cap	1.9B 196M 172M 158M 148M 278M 18.47B 284M 736M 9.13B 735M 719M 31.66B	P/E 2024	-14.5x	P/E 2025	-3.86x
Enterprise Value	1.36B 140M 123M 113M 106M 199M 13.25B 203M 528M 6.55B 527M 516M 22.7B	EV / Sales 2024	1,077x	EV / Sales 2025	945x
Free-Float	-	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : InDex Pharmaceuticals Holding AB

11:42am	Flerie enters into merger plan with Biosergen	FW
06:00am	Flerie's Bonsai Biotherapeutics Receives Clinical Trial Application Approval for Lead Drug Candidate	MT
04:11am	Flerie portfolio company Bonsai gets clearance for clinical trial application	FW
06-24	15 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
06-23	21 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
06-18	15 stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
06-15	Calendar Monday, June 15	FW
06-12	Calendar Monday June 15 - Friday June 19	FW
06-12	Calendar Monday June 15	FW
06-11	Ten stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
06-10	12 stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
06-05	Flerie Affirms Confidence in Xspray Pharma's Cancer Drug After US FDA Letter	MT
06-05	Six stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW

More news

Analysts' recommendations: InDex Pharmaceuticals Holding AB

01-22	DNB Carnegie Lowers Price Target for Flerie to 45 Kronor (52), Reiterates Buy	FW
25-10-24	Affärsvärlden Issues Buy Recommendation for Flerie	FW
25-10-23	DNB Carnegie Lowers Price Target for Flerie to 52 Kronor (60), Reiterates Buy	FW
25-10-06	Flerie Sees Slight Increase in Net Asset Value in September	FW
25-08-06	DNB Carnegie Raises Target Price for Flerie to 60 Kronor (from 57), Reiterates Buy - BN	FW

More recommendations

Press Releases: InDex Pharmaceuticals Holding AB

04:07am	Flerie Invest : portfolio company Bonsai Biotherapeutics receives full approval of clinical trial application for TOL2 in myasthenia gravis	PU
06-15	Bulletin from the extraordinary general meeting of Flerie AB (publ) on 15 June 2026 at 10:00 CEST	PU
05-29	Flerie Invest : Change in the total number of shares and votes in Flerie AB (publ)	PU
04-30	Flerie Invest : Change in the total number of shares and votes in Flerie AB (publ)	PU
04-15	Flerie Invest : Interim report Q1 2026 Presentation	PU

More press releases

News in other languages: InDex Pharmaceuticals Holding AB

24-05-21	Borsa di Italia: tecnologia in orbita
24-05-21	Bolsa de Madrid: Tecnología en órbita
24-05-21	En Direct des Marchés : Sanofi, Airbus, Rubis, Atos, Valneva, Microsoft, Tesla, Generali...
24-05-21	La Tech en orbite

More news

Managers and Directors: InDex Pharmaceuticals Holding AB

Manager	Title	Age	Since
Ted Ingemar Jakob Fjällman CEO	Chief Executive Officer	48	2022-12-31
Cecilia Stureborg von Schéele DFI	Director of Finance/CFO	54	2023-12-31
Paula Andersson COO	Chief Operating Officer	39	2023-12-31

Director	Title	Age	Since
Cecilia Marie Edström BRD	Director/Board Member	60	2022-12-31
Thomas Bengt Eldered CHM	Chairman	66	2022-12-31
Anders Olof Adolf Ekblom BRD	Director/Board Member	72	2022-12-31

More insiders

InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused in pharmaceuticals development. The Company's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The Company also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohnâ€™s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.

Employees

Sector

Calendar

07-08 -

More about the company

	2024	2025
Net sales	2.6M 268K 235K 216K 203K 380K 25.25M 388K 1.01M 12.48M 1.01M 983K 43.27M	2.5M 257K 226K 208K 195K 365K 24.28M 373K 967K 12M 966K 945K 41.61M
Net income	-228M -23.47M -20.58M -18.97M -17.76M -33.3M -2.21B -33.99M -88.22M -1.09B -88.13M -86.21M -3.79B	-757M -77.92M -68.32M -62.97M -58.96M -111M -7.35B -113M -293M -3.63B -293M -286M -12.6B
Net Debt	-864M -88.97M -78.01M -71.91M -67.32M -126M -8.39B -129M -334M -4.15B -334M -327M -14.38B	-538M -55.39M -48.57M -44.77M -41.91M -78.6M -5.23B -80.23M -208M -2.58B -208M -203M -8.96B